Related Experiment Video
Updated: May 5, 2026
10:15
Utilizing Repetitive Transcranial Magnetic Stimulation to Improve Language Function in Stroke Patients with Chronic Non-fluent Aphasia
Published on: July 2, 2013
18.3K
Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary
Joshua G Cahan1,2,3,4, Borna Bonakdarpour1,2,4
1Mesulam Institute for Cognitive Neurology and Alzheimer's Disease, Feinberg School of Medicine, Northwestern University, Chicago, IL USA.
Current Treatment Options in Neurology
|September 23, 2025
Summary
Primary progressive aphasia (PPA) is a rare neurodegenerative disorder affecting language. Understanding its subtypes and associated proteinopathies aids diagnosis and tailored treatments for patients.
Area of Science:
- Neurodegenerative diseases
- Neurology
- Linguistics
Background:
- Primary progressive aphasia (PPA) is a rare neurodegenerative condition.
- It presents as a progressive decline in language functions.
- PPA is a variant of Alzheimer's disease or Frontotemporal Dementia.
Purpose of the Study:
- To explore the relationship between PPA subtypes and underlying proteinopathies.
- To guide clinicians in selecting appropriate biomarker testing.
- To inform tailored treatment strategies for PPA patients.
Main Methods:
- Classification of PPA into subtypes: agrammatic/nonfluent, semantic, and logopenic.
- Probabilistic association of subtypes with proteinopathies (amyloid, tau, TDP-43).
- Review of current diagnostic and therapeutic approaches.
Main Results:
- Each PPA subtype is linked to specific neurodegenerative pathologies.
- Biomarker testing is crucial for diagnostic accuracy.
- Treatment options include pharmacologic and non-pharmacologic strategies.
Conclusions:
- PPA subtypes offer insights into the brain's language anatomy.
- Personalized treatment based on PPA subtype and proteinopathy is essential.
- Advances in biomarker testing and treatment are improving patient care.
More Related Videos
Related Concept Videos
01:26Psychosis: Goals of Pharmacotherapy
711
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
711
01:15Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:29Alzheimer Disease l: Introduction
29
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
29